PathoGenetix, a Woburn, MA-based provider of rapid bacterial identification solutions, raised $10m in Series C financing.
Backers included Ascension Health Ventures, Excel Venture Management and Health Care Ventures.
The company intends to use the fund to continue to develop its Genome Sequence Scanning™ (GSS™) technology.
Led by Ann Merrifield, CEO, PathoGenetix develops an automated system for rapid bacterial identification. The automated RESOLUTION System, which includes the instrument, bioinformatics software and database, and pathogen-specific assays, will be commercially available in 2014 for use in food safety testing and foodborne illness outbreak investigations.
FinSMEs
30/10/2013